News Standard – Page 11 – Pharma Crystallization Summit

pcs2021-abstracts , pcs2021-speakers , pcs2021 , session-1-smarter-solid-form-pre-formulation-studies

Understanding and Controlling the API Form/Powder Property Risks in Drug Substance and Product Processes

June 16, 2020 wpadm

Dr. Shawn Yin, Bristol Myers Squibb

pcs2021-abstracts , pcs2021 , session-1-smarter-solid-form-pre-formulation-studies

Absolute Structure Determination of API Molecules by MicroED analysis of Cocrystals formed based on Cocrystal Propensity Prediction Calculations

June 16, 2020 wpadm

Drs. Chandler Greenwell (XtalPi), Harsh Shah (J-Star), and Jessica Bruhn (NIS)

pcs2020-abstracts , pcs2020 , session-1-smarter-solid-state-research-by-prediction-and-simulation

Locality, Strength, and Hierarchy of Intermolecular Interactions in Crystallization

June 16, 2020 wpadm

Self-assembling of molecules in crystallization is collectively driven by intermolecular interactions among the solute and solvent. Better understanding of nucleation mechanism may be perceived in light of the locality,...

pcs2021-abstracts , pcs2021 , session-2-particle-engineering-ds-dp-co-processing

Examples of Particle Engineering to Improve Patient Outcomes and Product Manufacturing

June 16, 2020 wpadm

Dr. Christopher Burcham, Eli Lilly and Company

pcs2021-abstracts , pcs2021 , session-2-particle-engineering-ds-dp-co-processing

Crystal Habit Modifications and Spherical Crystallization Design in Solution

June 16, 2020 wpadm

Prof. Junbo Gong, Tianjin University

pcs2021-abstracts , pcs2021 , session-2-particle-engineering-ds-dp-co-processing

Challenges and Opportunities in Optimizing Mechanical Properties of Drugs by Incorporating Excipients

June 16, 2020 wpadm

Prof. Calvin Changquan Sun, University of Minnesota

pcs2021-abstracts , pcs2021 , session-2-particle-engineering-ds-dp-co-processing

Bridging the Gap between Drug Substance and Drug Product Processing via Co-Processing

June 16, 2020 wpadm

Dr. Jian Wang, CfPC/J-Star/Porton

pcs2021-abstracts , pcs2021 , session-3-physical-property-based-crystallization-process-development

The Importance of Understanding and Characterising the Physical & Chemical Properties of APIs in the Digital Design of Drug Products

June 16, 2020 wpadm

Prof. Kevin Roberts, University of Leeds

pcs2021-abstracts , pcs2021 , session-3-physical-property-based-crystallization-process-development

Continuous Crystallization and Purification: The Role of Impurity Incorporation Mechanism in Non-Equilibrium Processes

June 16, 2020 wpadm

Prof. Allan Myerson, MIT

pcs2021-abstracts , pcs2021 , session-3-physical-property-based-crystallization-process-development

Co-Crystals Platform to Improve Physical Properties of Early Intermediates during API Manufacturing Process

June 16, 2020 wpadm

Dr. Samir Kulkarni, Pfizer

Office Address

Pinterest

Social List

Blog Standard

Understanding and Controlling the API Form/Powder Property Risks in Drug Substance and Product Processes

Absolute Structure Determination of API Molecules by MicroED analysis of Cocrystals formed based on Cocrystal Propensity Prediction Calculations

Locality, Strength, and Hierarchy of Intermolecular Interactions in Crystallization

Examples of Particle Engineering to Improve Patient Outcomes and Product Manufacturing

Crystal Habit Modifications and Spherical Crystallization Design in Solution

Challenges and Opportunities in Optimizing Mechanical Properties of Drugs by Incorporating Excipients

Bridging the Gap between Drug Substance and Drug Product Processing via Co-Processing

The Importance of Understanding and Characterising the Physical & Chemical Properties of APIs in the Digital Design of Drug Products

Continuous Crystallization and Purification: The Role of Impurity Incorporation Mechanism in Non-Equilibrium Processes

Co-Crystals Platform to Improve Physical Properties of Early Intermediates during API Manufacturing Process